Trial Profile
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary) ; Lanraplenib (Primary) ; Tirabrutinib (Primary)
- Indications Sjogren's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Gilead Sciences
- 14 Nov 2022 Results investigating biomarkers predictive of treatment response and possible relationships between baseline (BL) interferon (IFN) activity and clinical response rates to FIL, TIRA, and LAN using the novel Composite of Relevant Endpoints for Sjogrens Syndrome (CRESS) score as a clinical endpoint presented at the ACR Convergence 2022
- 04 Apr 2022 Results characterizing filgotinib, lanraplenib, and tirabrutinib safety and efficacy in patients with active Sjogren's syndrome, published in the Rheumatology.
- 07 Oct 2019 Status changed from active, no longer recruiting to completed.